Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Status
Active
Cancer Type
Oral Cancer
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT02655822
Protocol IDs
CPI-444-001 (primary)
NCI-2016-00227
Study Sponsor
Corvus Pharmaceuticals, Inc.

Summary

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small

molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune

system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444

as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various

solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine

suppresses the anti-tumor activity of T cells and other immune cells.

Objectives

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small

molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune

system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444

as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor.

CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the

anti-tumor activity of T cells and other immune cells.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.